Phase 2 N=92 Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
Gastroparesis · Dyspepsia
Primary: Gastric Emptying Half-time (T1/2) of Solids — 128.7; 125.8; 246.4; 198.4 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=54 Gulf War Digestive Health Study
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
N/A N=99,314 Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing
Colorectal Cancer · Stomach Disease
Primary: Incidence of Stomach Cancer — 49; 59 Participants
N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
N/A N=60 Proton Pump Inhibitors and Dysbiosis in Cirrhosis
Cirrhosis · Healthy
Primary: Number of Patients With Overgrowth of Oral Microbiota in Their Stool After PPI Therapy Withdrawal or Initiation — 45; 15 Participants
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05
Phase 2 N=104 Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus
Dyspepsia · Diabetes Mellitus With Gastrointestinal Symptoms
Primary: Mean Intestinal Chemosensitivity to Lipids Perfusion — 0.22; 0.36; 0.55; 0.65 score on a scale — p=0.06
Phase 3 N=58 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
Gastroparesis
Primary: Symptom of Vomiting Associated With Gastroparesis — 1.82; 2.68; 0.17; 1.20 Patient Self-reported Symptom Score
N/A N=99 Fear, Gastrointestinal Distress, and Interoception: Physiological and Psychological Mechanisms in Eating Disorders
Feeding and Eating Disorders
Primary: Subjective Rating of Fear — -36.9444; -23.9219; -47.3611; 85.6250 units on scale*minutes — p=.879
N/A N=53 Stress in Inflammatory Bowel Disease
Inflammatory Bowel Diseases · Psychological
Primary: Retention Rate — 23; 25; 19; 22 Participants
N/A N=17 Dietetic Efficacy of Mare's Milk for Patients With Chronic Inflammatory Bowel Diseases
Ulcerative Colitis · Crohns Disease
Primary: Score of Crohn´s Disease and/or Ulcerative Colitis — 58; 1.8; 43; 1.2 units on a scale
N/A N=6 Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers
Pharmacodynamic
Primary: Change in Gastric pH After Administration of Betaine Hydrochloride (HCl) — 4.54 units on a scale
N/A N=50 Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease
Inflammatory Bowel Disease · Glycogen Storage Disease Type Ia
Primary: Serologic, Genetic and Inflammatory Markers Consistent With Inflammatory Bowel Disease — 11 participants testing positive
N/A N=76 Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch
Idiopathic Parkinson's Disease
Primary: Change From Baseline to Visit 3 in the Assessment of Intensity of Gastrointestinal (GI) Complaints for Any Reason as Per Visual Analogue Scale (VAS) — -26.8 millimeter…
N/A N=76 Proteiomic Fingerprints of Gastric Juice
Gastric Cancer
Primary: Number of Participants With Accurate Diagnosis for Gastric Cancer — 27; 44 participants
Phase 2 N=12 Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
Stage III Gastric Cancer · Stage IV Gastric Cancer
Primary: Observed Response Rate. — 0 Percentage of Participants
Phase 2 N=20 Effect of Secretin in Functional Dyspepsia and Healthy Subjects
Dyspepsia · Healthy
Primary: Maximum Satiation — 892.5; 951.75; 655.5; 892.5 mL — p=0.12
N/A N=100 Gastric Ultrasound
Surgery
Primary: Aspiration Risk Grade — 30; 30; 20; 9 Participants
Phase 2 N=17 A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
Recurrent Gastric Cancer · Stage IV Gastric Cancer
Primary: Response Rate — 0 percentage of patients responding
N/A N=1,881 Impact of Diet on Functional Gastrointestinal Symptoms
Gastrointestinal Disorder, Functional
Primary: Most Common Triggers for Food-related GI Symptoms (Top 5) — 881; 494; 469; 460 Participants
Phase 2 N=20 A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)
Gastroparesis · Diabetes Mellitus
Primary: Venous Plasma Heme-oxygenase 1 (HO1) Protein Concentration — 1.6; 1.5; 10.6; 1.5 ng/mL — p=0.0002
N/A N=455 The Association With Peptic Ulcer Disease and Hepatic Vein Pressure Gradient
Cirrhosis · Chronic Liver Disease
Primary: The Association of HVPG and PUD in Patients With Liver Cirrhosis — 14.5; 15.3 mmHg
N/A N=63 Gastric Outlet Obstructions Tailored Covered Stents for GOO
Gastric Outlet Obstruction
Primary: Efficiency of Stents — 1; 7 participants